Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer

Part of paid clinical trials in Charleston, South Carolina.

Sponsor
Medical University of South Carolina
Study ID
NCT00089102
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • gemcitabine hydrochloride — DRUG
    1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
  • irinotecan hydrochloride — DRUG
    100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle

Study Details

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan works in treating patients with locally advanced unresectable or metastatic kidney cancer.

Key Dates

Start date
Sep 30, 2003
Status verified
Jul 2018
Primary completion
Jul 31, 2009
Completion
Jul 31, 2009

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Gemcitabine + Irinotecan

Primary Outcome Measure

Response Proportion [ Time Frame: From registration until time of complete response or partial response ]

Locations (2)

FacilityCityStateZIPSite coordinators
Hollings Cancer Center at Medical University of South CarolinaCharlestonSouth Carolina29425-
Gibbs Regional Cancer Center at Spartanburg Regional Medical CenterSpartanburgSouth Carolina29303-

Find similar trials in Charleston, SC

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Hollings Cancer Center at Medical University of South Carolina· Charleston, SCGibbs Regional Cancer Center at Spartanburg Regional Medical Center· Spartanburg, SC

Related Studies